Vaccinating with AREXVY is a conversation worth having.
ACIP recommends a single dose of RSV vaccine, including AREXVY, for adults aged 60 years and older, using shared clinical decision-making. Shared clinical decision-making recommendations are individually based and informed by a decision process between the healthcare provider and the patient.\textsuperscript{1,2}

IN 2021, IT WAS ESTIMATED THAT

\begin{center}
\textbf{23.4\%}
\end{center}

OF PEOPLE IN THE UNITED STATES WERE \textit{≥}60 YEARS OF AGE.\textsuperscript{3}

**ESTABLISH** | Set up protocols for appropriate patient identification to ensure patients aren't missed.

**RECOMMEND** | Talk to your patients about RSV and its risks for older adults. Discuss vaccination with AREXVY for appropriate patients.

**SCHEDULE** | Help your patients schedule their appointment for vaccination with AREXVY.

\textbf{Indication}

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

\textbf{Important Safety Information}

- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY

Please see additional Important Safety Information for AREXVY on the reverse side and accompanying full Prescribing Information, also available at AREXVYhcp.com.
Help your appropriate patients aged 60 years and older understand the risks of RSV and the importance of following through with vaccination. Here are some frequently asked questions that may help inform your strong recommendation for AREXVY.

<table>
<thead>
<tr>
<th>Q:</th>
<th>What is RSV and who is at risk for severe RSV infection?</th>
</tr>
</thead>
<tbody>
<tr>
<td>A:</td>
<td>RSV is a common and contagious virus that typically produces mild, cold-like symptoms. Older adults, including those with certain comorbidities, such as COPD, asthma, and CHF, are at risk for severe infection.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Q:</th>
<th>When should my patients be vaccinated with AREXVY?</th>
</tr>
</thead>
<tbody>
<tr>
<td>A:</td>
<td>RSV season typically takes place through fall and winter, though regional variations may exist. Talk to your patients about AREXVY when discussing seasonal influenza vaccine.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Q:</th>
<th>Will AREXVY be covered by insurance?</th>
</tr>
</thead>
<tbody>
<tr>
<td>A:</td>
<td>Please scan the QR code to find out more information about coverage.</td>
</tr>
</tbody>
</table>

CHF=chronic heart failure; COPD=chronic obstructive pulmonary disease; RSV=respiratory syncytial virus.

Important Safety Information (cont.)

- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting.
- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY.
- The most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
- Vaccination with AREXVY may not result in protection of all vaccine recipients.

Please see additional Important Safety Information for AREXVY on the reverse side and accompanying full Prescribing Information, also available at AREXVYhcp.com.